SEI Investments
CERE

SEI Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

SEI Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,414
Closed -$508K – 2807
2024
Q2 		$508K Sell
12,414
-3,193
-20% -$133K ﹤0.01% 2144
2024
Q1 		$660K Buy
+15,607
New +$656K ﹤0.01% 2022
2023
Q3 		– Sell
-14,960
Closed -$476K – 2714
2023
Q2 		$476K Buy
14,960
+2,263
+18% +$69.5K ﹤0.01% 2151
2023
Q1 		$310K Sell
12,697
-10,330
-45% -$303K ﹤0.01% 2325
2022
Q4 		$726K Sell
23,027
-624
-3% -$17.6K ﹤0.01% 1870
2022
Q3 		$668K Buy
23,651
+12,520
+112% +$373K ﹤0.01% 1961
2022
Q2 		$294K Buy
+11,131
New +$316K ﹤0.01% 2333
2022
Q1 		– Sell
-19,608
Closed -$636K – 2682
2021
Q4 		$636K Sell
19,608
-5,339
-21% -$188K ﹤0.01% 2008
2021
Q3 		$736K Sell
24,947
-5,347
-18% -$150K ﹤0.01% 1897
2021
Q2 		$776K Buy
+30,294
New +$434K ﹤0.01% 1916

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

SEI Investments's CERE Position: Q3 2024 in Review

SEI Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12,414 shares — an estimated $508K sold.

SEI Investments first reported a position in CERE in Q2 2021 and held it in 10 quarters. The position peaked at $776K in Q2 2021. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • SEI Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • SEI Investments sold 12,414 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $508K.
  • SEI Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • SEI Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $776K in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on SEI Investments's 13F filing for Q3 2024, filed 12 Nov 2024.